Biotech | April 03, 2022
New data indicate molnupiravir eliminates Covid-19 rapidly
Among patients with infectious virus at baseline, no patients who received Lagevrio had infectious virus at days 3, 5 or 10
Among patients with infectious virus at baseline, no patients who received Lagevrio had infectious virus at days 3, 5 or 10
An estimated 21 million American women experience BV
Companies to leverage proprietary IgM antibody technology platform to discover agonists against three oncology targets and three immunology/inflammation targets
The summit also saw the launch of two important reports- Multi-Regional Clinical Trials (MRCT) and Value of OTC in India
World-leading companies, as well as small innovative research groups, regularly partner with Medanex for their outstanding cardiovascular services and timely, efficacious study outcomes.
Dupixent peak sales ambition raised to more than €13 billion
AbbVie to present 30 abstracts demonstrating its leadership in neuroscience, including continued migraine treatment research across the spectrum of the disease, commitment to patients with advanced Parkinson's disease, and new studies in spasticity and cervical dystonia
Veritaz has over 40 brands marketed across the acute and critical care therapeutic segments
In May 2021, Daiichi Sankyo had submitted a supplemental new drug application (sNDA) for Tarlige tablets based on results from a phase 3 trial in patients with CNP
Clinical improvements were consistent across patient subgroups including age, gender, ethnicity, and IL-36 gene mutation status
Subscribe To Our Newsletter & Stay Updated
